119 related articles for article (PubMed ID: 11516372)
1. The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report.
Muise A; Arbess G
Int J STD AIDS; 2001 Sep; 12(9):612-3. PubMed ID: 11516372
[TBL] [Abstract][Full Text] [Related]
2. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
[TBL] [Abstract][Full Text] [Related]
3. [HAART influences the lipids].
Behrens G
MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
[No Abstract] [Full Text] [Related]
4. Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.
Badiou S; Dupuy AM; Baillat V; Fabre J; Tur MD; Cristol JP; Reynes J
Clin Lab; 2003; 49(1-2):11-3. PubMed ID: 12593470
[No Abstract] [Full Text] [Related]
5. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
Vella S; Palmisano L
J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
[No Abstract] [Full Text] [Related]
6. ["HAART-attack" in young female HIV-patient].
Pittl U; Keller DI; Kaiser CA; Battegay M; Pfisterer ME; Linka A
Internist (Berl); 2006 Sep; 47(9):939-40, 942-3. PubMed ID: 16838185
[TBL] [Abstract][Full Text] [Related]
7. [Myocardial infarction in the course of antiretroviral therapy with protease inhibitor].
Buccoliero G; Lonero G; Rollo MA; Cristiano L; Romanelli C; Loperfido P; Chimienti A; Angelini P; Resta F
Recenti Prog Med; 2003 Jun; 94(6):264-6. PubMed ID: 12793098
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
9. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
Hirsch HH; Battegay M
Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
[TBL] [Abstract][Full Text] [Related]
10. Subclinical contractility impairment in HIV-infected patients: dependence on the class of antiretroviral drugs.
Mercuro G; Cadeddu C; Nocco S; Deidda M; Mercuro S; Piano P; Ortu F; Manconi PE
Int J Cardiol; 2013 Sep; 168(2):1538-9. PubMed ID: 23287696
[No Abstract] [Full Text] [Related]
11. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
12. Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study.
Woolley IJ; Li X; Jacobson LP; Palella FJ; Ostergaard L
Sex Health; 2007 Jun; 4(2):111-9. PubMed ID: 17524289
[TBL] [Abstract][Full Text] [Related]
13. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
15. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
17. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy.
Rodriguez-Guardado A; Maradona JA; Carton JA; Asensi V
AIDS; 2002 Jul; 16(10):1434-6. PubMed ID: 12131227
[No Abstract] [Full Text] [Related]
18. HIV-1, HAART and bone metabolism.
Borderi M; Farneti B; Tampellini L; Giuliani R; Verucchi G; Vescini F; Caudarella R; Chiodo F
New Microbiol; 2002 Jul; 25(3):375-84. PubMed ID: 12173783
[TBL] [Abstract][Full Text] [Related]
19. Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy.
Carling RS; Hextall R; DeSilva PA; Barth JH
Ann Clin Biochem; 2002 Jul; 39(Pt 4):409-13. PubMed ID: 12117447
[TBL] [Abstract][Full Text] [Related]
20. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART.
Uccelli MC; Torti C; Lapadula G; Labate L; Cologni G; Tirelli V; Moretti F; Costarelli S; Quiros-Roldan E; Carosi G
Ann Nutr Metab; 2006; 50(3):247-52. PubMed ID: 16508252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
